Kornimate/medical-research-clean huggingface dataset:
establishing ambulatory glucose profiles for people without diabetes using cgm data

Conditions: NonDiabetes; Glucose Variability; CGM

Summary: in a previous study we used the freestyle navigator continuous glucose monitoring (cgm) system to obtain 30 days of glucose measurements from 30 people with diabetes treated with insulin. the purpose of this study is to characterize glycemia (glucose) control in 30 people without diabetes and to compare these data to the 30 people with diabetes from a previous study. through this approach it may be possible to develop a means of establishing a model of normal glucose patterns and a basis of comparison with glucose patterns in people with diabetes.


Eligibility criteria:
inclusion criteria: * male or female * within normal range for two hour ogtt glucose level (\<140 mg/dl) * within normal range for fasting glucose level (\<100 mg/dl) * within normal range for total insulin level as measured by radioimmunoassay * bmi \<30kg/m2 * age 21-75 years of age, inclusive (15 subjects in the 21-49 years of age group, 15 subjects in the 50-75 years of age group) * willing to give informed consent * capable of following the protocol and instructions of study staff * available for scheduled visits * access to telephone communications exclusion criteria: * under 21 years of age or over 75 years of age * abnormal ogtt * previous history of diabetes * outside of normal insulin range * bmi \> 30kg/m2 * unable to follow protocol * unable to read and write in english * skin abnormalities at insertion sites * allergy to adhesives * any concomitant medical condition that would likely affect the evaluation of device performance * taken prednisone or cortisone medications in the previous 30 days * blood transfusion within the past 90 days * blood donation within the past 30 days * metabolic syndrome (ncep atp iii guidelines) * any medical condition that would affect glucose (per investigator decision)

Keywords: nondiabetes cgm
chuspan pan bp treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors

Conditions: Polyarteritis Nodosa; Microscopic Polyangiitis

Summary: to assess the efficacy of systemic corticosteroids alone as first-line treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors as defined by the five-factor score (ffs=0), and to compare the efficacy and safety of azathioprine vs pulse cyclophosphamide as adjunctive immunosuppressive therapy to treat failure or relapse.

all patients initially treated with systemic corticosteroids alone: optional iv methylprednisolone pulse (15 mg/kg) at treatment start followed by oral prednisone (1 mg/kg/day) according to a tapering schedule. treating physicians allowed to treat minor relapses with corticosteroids without referring the patient for randomization, as long as the prednisone dose did not exceed 0.5 mg/kg for 1 month. patients in whom prednisone doses could not be tapered below 20 mg, those who failed to enter remission and those who relapsed were randomized to receive either 6 months of oral azathioprine (2mg/kg/day) or 6 cyclophosphamide pulses (0.6g/m2 d1, d15, d30 then every month)

Eligibility criteria:
inclusion criteria: * men and women with newly diagnosed polyarteritis nodosa or microscopic polyangiitis; * absence of poor prognostic factors as defined by the five-factor score (serum creatinine \> 140 μmol/l or 1.58 mg/dl, proteinuria \> 1 g/day, severe gastrointestinal tract involvement, specific cardiomyopathy and/or central nervous system involvement; * written informed consent. * both genders eligible; * age ≥ 15 years. exclusion criteria: * age \< 15 years, previously treated systemic vasculitis; * history of cancer; * pregnant or breast-feeding women; * psychiatric disorders that might compromise compliance with therapy; * contraindication to study drug; * other ongoing therapeutic trial; * concomitant viral hepatitis b or c or human immunodeficiency virus (hiv) infection

Keywords: polyarteritis vasculitis therapy cyclophosphamide azathioprine
a prpct to assess the efficacy & safety of chronic pain rehab training software for alleviating chronic secondary musculoskeletal pain

Conditions: Chronic Pain

Summary: a prospective, randomized, parallel-controlled clinical trial to evaluate the effectiveness and safety of chronic pain rehabilitation training software in assisting in the relief of chronic secondary musculoskeletal pain

a prpct to assess the efficacy \& safety of chronic pain rehab training software for alleviating chronic secondary musculoskeletal pain

Eligibility criteria:
inclusion criteria: * males and females ≥18 years old. * average pain intensity≥4 on a 0-10 numerical rating scale (nrs) in the past 24 hours. * be able to communicate in chinese. * be able to read and write chinese. * willing to comply with study procedures and restrictions. * willing and able to sign informed consent. exclusion criteria: * shingles on the eyes, ears, head, face, or hands. * trigeminal neuralgia. * severe vision impairment. (patients with clear vision wearing glasses or contact lenses are allowed) * severe hearing impairment. * disease or medical condition predisposing to nausea or dizziness, such as insufficient blood supply to the brain, vestibular dysfunction,cholecystitis, etc. * history of severe motion sickness. * injury to eyes, ears, face, or neck that impedes comfortable use of mixed reality. * injury or dysfunction of hands or upper limbs that impedes comfortable use of mixed reality. * diagnosis of cognitive impairment, epilepsy, dementia, migraines or other neurological diseases that may prevent the use of mixed reality. * history of mental illness, including depression, generalized anxiety disorder, schizophrenia, etc. * females currently pregnant. * current or completion of participation within 4 weeks before screening in any interventional clinical study * patients whom the investigator considers not suitable to participate in this study.

Keywords: pain visual pain score rehab training software anxious depressed
the specific lung elastance in acute lung injury/acute respiratory distress syndrome (ali/ards) patients in supine and prone position

Conditions: Acute Lung Injury; Acute Respiratory Distress Syndrome

Summary: the investigators aim is to study the specific lung elastance in ali/ards patients during invasive mechanical ventilation, in supine and prone position.

in sedated and paralyzed ali/ards patients, we study and compare the specific lung elastance in supine and prone position during invasive mechanical ventilation.

Eligibility criteria:
inclusion criteria: * ali/ards patients during invasive mechanical ventilation exclusion criteria: * haemodynamic failure, pneumothorax

Keywords: gas exchange respiratory mechanics ventilator induced lung injury
prehospital recognition and identification of unspecific symptoms

Conditions: Serious Condition; Morality

Summary: this study evaluates the predictive value of soluvent urokinase plasminogen activator receptor (supar) and lactate with respect to serious conditions among patients presenting to the ems with unspecific symptoms.


Eligibility criteria:
inclusion criteria: * unspecific symptoms (not feeling well, decreased general health condition, unable to cope with usual daily activities, feeling weak) * normal vital signs * transported to ed * able to give informed consent/ next of kin gives informed consent exclusion criteria: * specific symptoms * under 18 years of age * stays home / other caregiver than ed * referral from caregiver * no personal numer (social security number)

Keywords: unspecific symptoms soluvent urokinase plasminogen activator receptor lactate emergency medical services
testing ascensia contour glucometer for the measurement of blood glucose

Conditions: Gestational Diabetes

Summary: present practice: measurement of fasting glucose values in 2nd trimester of pregnancy, if above 4.8 mmol/l, a glucose tolerance test is performed. (two-step procedure: 1. appointment for the fasting glucose measurement, 2. appointment for the glucose tolerance test)

present practice: measurement of fasting glucose values in 2nd trimester of pregnancy, if above 4.8 mmol/l, a glucose tolerance test is performed. (two-step procedure: 1. appointment for the fasting glucose measurement, 2. appointment for the glucose tolerance test) study: testing of reliability and applicability of the ascensia contour glucometer, bayer. comparison of 100 fasting glucose values measured in venous plasma by the hexokinase method in the laboratory with 100 fasting glucose values measured in capillary whole blood on the ascensia contour glucometer outcome: if ascensia contour glucometer shows applicable accuracy (narrow scatter of values), the two-step procedure should be replaced by one-step procedure: 1 only one appointment for the measurement of the fasting glucose value in capillary whole blood on ascensia contour glucometer and if above 4.8 mmol/l glucose tolerance test on the same day

Eligibility criteria:
inclusion criteria: * healthy pregnant women in 2nd trimester of pregnancy scheduled for the measurement of fasting glucose value exclusion criteria: * pregnant women with pre-existent (type 1 or 2) diabetes or already diagnosed diabetes of pregnancy

Keywords: gestational diabetes, screening, glucose monitoring
efficacy of serratus anterior plane block mastectomy

Conditions: Postoperative Pain; Postoperative Complications

Summary: breast cancer is the main common cancer among females. . inadequate control of pain may later develop into chronic pain syndrome (paraesthesias, phantom breast pain, and intercostobrachial neuralgia) in 25-40% of the patients .

the aim of this study is to compare the efficacy of ultrasound-guided serratus anterior plane block with bupivacaine/ magnesium versus bupivacaine/ nalbuphine in breast cancer surgery. patients and methods nclusion criteria: -asa i and ii female patients, age 25-60 undergoing breast cancer surgery exclusion criteria: * patient refusal * contraindications for regional blocks (eg. infection at the injection site, coagulopathy) * allergy to the drugs used in the study * chronic pain therapy, * bmi more than 30 kg/m2

Eligibility criteria:
inclusion criteria: * asa i and ii female patients, age 25-60 undergoing breast cancer surgery exclusion criteria: * -patient refusal * contraindications for regional blocks (eg. infection at the injection site, coagulopathy) * allergy to the drugs used in the study * chronic pain therapy, * bmi more than 30 kg/m2
artificial intelligence assisted insulin titration system

Conditions: Type 2 Diabetes

Summary: this is a single-center, open-labeled, parallel group, randomized controlled trial to access the effect and safety of the artificial intelligence assisted insulin titration system in patients with type 2 diabetes mellitus.

the study enrolls 44 patients with type 2 diabetes in zhongshan hospital who are on treatment with insulin for at least 3 months. they are randomly allocated into 2 groups at a ratio of 1:1 after screening for the inclusion and exclusion criteria. patients in the intervention group receive insulin regimen set by the ai assisted system and patients in control group receive insulin regimen set by physicians. this study will be conducted in the department of endocrinology, zhongshan hospital,fudan university and consist of a 7-day intervention period. patient allocation will be stratified by hba1c, bmi and previous total insulin doses.the primary endpoint is the percentage of time of sensor glucose measurements in targeted range (3.9-10 mmol/l) during the 7-days trial period.

Eligibility criteria:
inclusion criteria: * men or women aged 18-75 years old; * subjects who had been diagnosed with type 2 diabetes; * subjects who are on treatment with insulin for at least 3 months; * hba1c: 7.0%-11.0%. exclusion criteria: * subjects with acute complications of diabetes such as ketoacidosis or hyperglycemic hyperosmolar state; * subjects who change the insulin regimens during hospitalization; * bmi ≥ 45kg/m2; * women who are pregnant or nursing; * subjects with severe cardiac, hepatic, renal or general diseases; * subjects with psychiatric disorders or impaired cognitive function; * subjects with severe edema, infections or peripheral circulation disorders; * patients treated with surgery during hospitalization; * subjects that are, in the judgement of the investigator, unlikely to comply with the protocol.
effects of armolipid plus on cholesterol levels and endothelial function

Conditions: Hyperlipidemia; Endothelial Dysfunction

Summary: some nutraceuticals are often advised for their lipid lowering effects. although many clinical trials have been conducted to assess their efficacy many doubts remain whether they could be considered an effective alternative to statins therapy. the aim of this study was to evaluate the lipid lowering effects and the improvement of endothelial dysfunction in patients with hyperlipidemia, treated with a nutraceutical product (armolipid plus)


Eligibility criteria:
inclusion criteria: * males and females aged between 18 and 70 * total cholesterol levels \> 220 mg/dl and ldl-cholesterol \> 130 mg/dl; * patients with concomitant pathology such as diabetes, chronic heart failure, coronary artery disease, arterial hypertension, dysthyroidism, were admitted as long as stable in the previous three months exclusion criteria: * proven intolerance to an armolipid plus compound * pregnant women, and women planning to conceive * patients in therapy with lipid lowering drugs within the previous 6 weeks * triglycerides concentration \> 500mg/dl were excluded.
gut microbiome & gastrointestinal toxicities as determinants of response to neoadjuvant chemo for advanced breast cancer

Conditions: Breast Cancer

Summary: the purpose of this research is to test whether bacteria that normally live in the intestines play a role in fighting cancer. it is believed that the development and behavior of these immune cells may be influenced by bacteria and other microorganisms living in the gut. in turn, the activities of these immune cells could work with anti-cancer therapies to make them more, or less, effective.

many chemotherapeutic agents compromise the integrity of the mucosal barrier in the gut, allowing translocation of gram-positive bacteria in secondary lymphoid organs. while this has, until recently, been considered an undesirable side-effect, it may also represent one mechanism by which chemotherapy stimulates an effective anti-cancer immune response. the purpose of this research is to test whether bacteria that normally live in the intestines play a role in fighting cancer. it is believed that the development and behavior of these immune cells may be influenced by bacteria and other microorganisms living in the gut. in turn, the activities of these immune cells could work with anti-cancer therapies to make them more, or less, effective. the hypothesis is that gut microbial composition can influence immune response to the tumor, resulting in inter-individual differences in the response to anti-cancer therapies.

Eligibility criteria:
inclusion criteria: * diagnosed with invasive breast cancer and prescribed a regimen that includes neo-adjuvant therapy prior to breast surgery. * able to provide informed consent. exclusion criteria: * history of previous malignancy, other than non-melanoma skin cancers * inability to tolerate phlebotomy * immunosuppressive therapy for any other condition * fever or active uncontrolled infection in the last 4 weeks * inflammatory bowel disease * surgery of the stomach, small or large intestines, appendectomy, gastric bypass or gastric banding in the past 6 months. * active autoimmune disease, including, but not limited to, systemic lupus erythematosus (sle), multiple sclerosis (ms), ankylosing spondylitis

Keywords: breast cancer
prognostic assessment of different pattern of bifurcation restenosis

Conditions: In-stent Coronary Artery Restenosis

Summary: the latina registry aims at assessing a new classification of bifurcation restenosis in the prediction of major adverse cardiac events in patients who have previously undergone a succesful percutaneous bifurcation intervention.


Eligibility criteria:
inclusion criteria: * age \>18 years * restenosis involving a coronary bifurcation previously treated percutaneously exclusion criteria: * life expectancy \>1 year
yoga for aromatase inhibitor-related knee pain relief in breast cancer patients

Conditions: Breast Cancer; Aromatase Inhibitor; Yoga; Knee Pain

Summary: the purpose of the study was to investigate the therapeutic effect of yoga on aromatic inhibitor-induced chronic knee pain in patients with breast cancer.

estrogen plays a critical role in breast cancer growth in pre-and post-menopausal women. the aromatic catalyzer has relationship with biosynthesis of estrogen, therefore, aromatic inhibitors became as a standard therapy of breast cancer in post-menopausal women. arthralgia and joint stiffness are most common side effect in aromatic inhibitor treatment. yoga is benefit for the patients with chronic pain improvement, and also can improve quality of life. therefore, the purpose of the present study was to investigate the therapeutic effect of yoga on aromatic inhibitor-induced chronic knee pain in patients with breast cancer.the investigators designed a crossover study, a total of 60 patients divided equally to control group (massage for 6 weeks in home care) and treatment group (yoga treatment for 12 times/6 weeks). there is two weeks wash out period after finishing 6 weeks treatment, and then the patients in control group changed to treatment, in contrast, the patients in the treatment changed to control group. the assessment time was pre-treatment (vision 1), finishing 6 weeks treatment (vision), finishing 6 weeks treatment after crossover (vision 3). the major assessment was brief pain inventory scores changed the results in the present study predict yoga treatment for 6 weeks can improve aromatic inhibitor-induced knee pain and also can improve quality of life in patients with breast cancer.

Eligibility criteria:
inclusion criteria: diagnosed with breast cancer and is taking an aromatic ring enzyme inhibitor. knee joint pain for more than three months. ages are over 20 years old and under 70 years old. exclusion criteria: at the same time, there are multiple sources of pain associated with non-breast cancer, such as visceral pain, traumatic pain, which must be excluded by the moderator. addicted drug abusers, subject to the judgment of the host. women who may be pregnant, pregnant women, within three months after childbirth. have a serious mental illness or an unstable mental state, which will affect the clinical assessment. severe hearing impairment, visual impairment, or dementia. it is not easy to measure by the host. limb edema and severe skin damage are not suitable for yoga practitioners by the physician. the spinal lesions are excessively severe, affecting the normal function of the operation, and the test cannot be completed. have been a yoga practitioner for nearly a month, or a regular exerciser for over 90 minutes per week for the past month. cancer has been transferred (stage iv)
real world effectiveness of oral semaglutide in thailand participants with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this study aims to describe the effectiveness of oral semaglutide on glycemic control and body weight control and describe characteristics of type 2 diabetes (t2d) adult patients who are being treated with oral semaglutide in thailand. data of eligible patients with t2d will be collected via electronic medical record or paper-format chart review to assess the effectiveness of oral semaglutide. total study duration for the individual patient will be six months from baseline. the study duration expands within the window period will be 12 months from baseline which will be the optional visit.


Eligibility criteria:
inclusion criteria: * adult thai male or female patients aged greater than or equal to (≥) 18 years. * diagnosed with t2d either through international classification of diseases (icd) code or by physician's description such as documentation in the medical record, and who have not previously been treated with injectable glucose-lowering medication. * at least one recent or closest glycated haemoglobin (hba1c) test value available and documented less than or equal to 12 weeks prior to the initiation of oral semaglutide. * had initiated oral semaglutide for diabetes during the target selection period of april 2022 to december 2023. all required data for collection should already be accessible prior to the initiation of data collection. * treated with oral semaglutide for at least 6 months without interruption or discontinuation. exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study (if applicable). * participants with any diagnosis of type 1 diabetes (t1d). * medical records documenting prior or ongoing treatment with injectable glucose-lowering treatment.
characterization of cd responders to vedolizumab

Conditions: Crohn Disease; Ulcerative Colitis

Summary: the purpose of this study is to characterize which patients with crohn's disease are likely to respond to standard of care to vedolizumab therapy.


Eligibility criteria:
inclusion criteria: 1. male or female ≥18 and ≤70 years old. 2. patients must be appropriate for baseline colonoscopy prior to induction therapy with vedolizumab. 3. patients must have active inflammatory disease as seen by colonoscopy. 3a-adult patients with moderately to severely active uc who have: 1. had an inadequate response with, lost response to, or were; 2. intolerant to a tumor necrosis factor (tnf) blocker or; 3. immunomodulator; or had an inadequate response with, were; 4. intolerant to, or demonstrated dependence on corticosteroids: * inducing and maintaining clinical response * inducing and maintaining clinical remission * improving endoscopic appearance of the mucosa * achieving corticosteroid-free remission 3b-adult patients with moderately to severely active cd who have 1. had an inadequate response with, lost response to, or were 2. intolerant to a tnf blocker or immunomodulator; or had an 3. inadequate response with, were intolerant to, or demonstrated 4. dependence on corticosteroids: * achieving clinical response * achieving clinical remission * achieving corticosteroid-free remission 4. patients will also have biochemical analysis with crp and fecal calprotectin prior to initiating treatment with vedolizumab. exclusion criteria: 1. patients that will not undergo colonoscopy at baseline prior to treatment with vedolizumab. 2. patients who do not have endoscopic or biochemical (crp, calprotectin) evidence of inflammation. 3. patients that have been on natalizumab within 12 weeks of beginning vedolizumab. 4. previous treatment with cyclosporine, thalidomide, or investigational drugs within 30 days of enrollment, prior treatment with vedolizumab 5. toxic megacolon 6. abdominal abscess 7. symptomatic colonic stricture 8. stoma 9. increased risk of infection (eg, active or latent tuberculosis, immunodeficiency) other clinically meaningful laboratory abnormalities: pregnancy or lactation, an unstable or uncontrolled medical disorder, colonic dysplasia or adenomas, and malignant neoplasms.

Keywords: inflammatory bowel disease (ibd) ibd cd uc vedolizumab vdz biomarkers response